Pharmacokinetic properties of the zinc agent polaprezinc in subjects with zinc deficiency
Not Applicable
- Conditions
- male subjects
- Registration Number
- JPRN-jRCT2080221593
- Lead Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Male
- Target Recruitment
- 6
Inclusion Criteria
subjects with low serum zinc concentrations (<70 microgram /dL)
- subjects with a body mass indexes (BMI) ranging from 18.5 to 25.0
Exclusion Criteria
- Subjects allergic to zinc, with abnormal hepatic, renal, or cardiac function, drug or alcohol dependence, tobacco use, or acute or chronic disorders that might interfere with drug absorption
- Subjects who received any medication within the 7 days prior to the date of drug administration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method plasma zinc concentration<br>N/A
- Secondary Outcome Measures
Name Time Method /A<br>N/A